Get to a sarcoma centre before anything is cut
The single most important thing on this page: sarcomas should be diagnosed and treated at a specialist sarcoma centre, and the biopsy should be planned by the surgeon who will do the operation. A biopsy placed in the wrong direction, or a lump "shelled out" by a well-meaning surgeon who assumed it was benign, can turn a limb-sparing operation into a much bigger one. This happens often enough to have a name in the literature — the "whoops procedure." If you have a deep lump larger than about 5 cm, or any lump that is growing, ask for referral before anything is cut.
Who is at risk
- Most people have no identifiable risk factor. Sarcoma is not caused by injury, diet or lifestyle.
- Previous radiation therapy — radiation-associated sarcomas arise in a previously treated field, usually 5–15 years later. Rare, but real.
- Inherited syndromes — Li-Fraumeni (TP53), neurofibromatosis type 1 (which predisposes to MPNST), hereditary retinoblastoma, Gardner syndrome.
- Chronic lymphoedema — long-standing limb swelling can rarely give rise to angiosarcoma.
- Chemical exposures — vinyl chloride and thorotrast, historically, for liver angiosarcoma.
- Age — soft tissue sarcoma is most often diagnosed after 55, but around 7% of cases occur before age 20.
Finding it early
There is no screening test. Sarcomas are found because someone notices a lump — and the difficulty is that most lumps are benign lipomas or cysts, so the ones that matter get dismissed.
The rule of thumb worth remembering — refer a lump that is:
- Larger than about 5 cm (roughly a golf ball)
- Deep — below the muscle layer rather than sitting just under the skin
- Growing, at any size
- Painful, or a previously stable lump that has changed
Any one of these justifies imaging and specialist referral. Retroperitoneal sarcomas, which grow in the back of the abdomen, cause no lump at all and are usually found late as vague abdominal fullness or on a scan done for something else.
"It is probably just a lipoma" is right most of the time. Get the ones that are large, deep, growing or painful imaged anyway.
How it’s diagnosed
MRI with contrast is the imaging test for limb and trunk lumps; CT is used for chest and abdomen. Then a core needle biopsy planned by the sarcoma surgical team — along a track that can be removed at the definitive operation.
Do not have an excisional biopsy of a suspicious deep lump. Removing it without planning contaminates the surrounding tissue and forces a much wider re-excision later.
Specialist pathology is essential: with more than 70 subtypes, diagnoses are revised at expert review more often than most people expect. Molecular testing — specific translocations in synovial sarcoma, myxoid liposarcoma, Ewing sarcoma; MDM2 amplification distinguishing well-differentiated liposarcoma from a benign lipoma — is frequently what settles the diagnosis.
Staging explained simply
Sarcoma staging combines grade, size, depth and spread, and grade carries more weight here than in most cancers. A large low-grade sarcoma may behave far better than a small high-grade one. Unlike most cancers, sarcomas usually spread through the bloodstream to the lungs rather than through lymph nodes.
| Stage | What it means in plain words |
|---|---|
| Stage I | Low grade, any size, no spread. Often treated with surgery alone. |
| Stage II | High grade, smaller tumour, no spread. |
| Stage III | High grade and larger, or spread to nearby lymph nodes (uncommon in sarcoma). |
| Stage IV | Spread to distant sites — most often the lungs. |
Grading and biology
Grade (1–3, based on differentiation, mitotic count and necrosis) is the strongest predictor of whether a sarcoma will spread. Low-grade sarcomas mostly recur locally; high-grade sarcomas carry real risk of lung metastasis.
Subtype determines everything else — liposarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, MPNST, angiosarcoma, GIST and dozens more. They differ in behaviour, in chemotherapy sensitivity, and in which drugs work. GIST in particular is treated with targeted therapy (imatinib) rather than conventional chemotherapy, and desmoid tumours do not metastasise at all and are increasingly managed with active surveillance rather than surgery.
How it’s treated
Surgery with wide margins is the foundation — removing the tumour with a cuff of normal tissue around it. Limb-sparing surgery is achievable for the large majority of extremity sarcomas.
Radiation is a core part of limb-sparing treatment, and this is important: combining radiation with more conservative surgery achieves the same local control as radical surgery or amputation, while preserving the limb. It can be given before surgery (smaller field, lower dose, but more wound-healing complications) or after (larger field, higher dose, more long-term stiffness). Both are standard; the trade-off is worth discussing.
Chemotherapy is used selectively — more clearly beneficial in chemo-sensitive subtypes such as synovial sarcoma, myxoid liposarcoma and Ewing sarcoma, less so in others. It is a genuine judgement call rather than automatic.
Targeted therapy for GIST and some other subtypes; metastasectomy — surgically removing lung metastases — can still be curative in selected patients, which is unusual and worth knowing.
Where CureRays fits: radiation for soft tissue sarcoma is core radiation oncology work, and it is the treatment that makes limb preservation possible.
What the guidelines say
In broad strokes: refer to a sarcoma centre before biopsy; image with MRI and biopsy along a planned track; obtain expert pathology with molecular testing; achieve wide surgical margins; add radiation before or after surgery for high-grade or large tumours to enable limb preservation; use chemotherapy selectively by subtype; treat GIST with targeted therapy; and consider surgical removal of limited lung metastases.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Source: NCI SEER Cancer Stat Facts: Soft Tissue Cancer (including heart), SEER 21 (excluding IL), 2015–2021. In 2025 an estimated 13,520 people will be diagnosed and about 5,410 will die of it.
| When it is found | Share of cases | 5-year relative survival |
|---|---|---|
| Localized — confined to where it started | 57% | 83.1% |
| Regional — spread to nearby lymph nodes | 18% | 59.7% |
| Distant — spread to other organs | 17% | 16.8% |
| Unstaged | 8% | 61.3% |
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
These figures average more than 70 different diseases, so they are a weaker guide here than on almost any other page. A low-grade liposarcoma and a high-grade undifferentiated pleomorphic sarcoma share a table and share almost nothing else. Ask your sarcoma team for figures matched to your subtype, grade, size and site.
Side effects and how we watch for them
Radiation to a limb: skin reaction and fatigue during treatment; longer term, stiffness and fibrosis of the treated muscle, joint restriction, lymphoedema, and a small risk of fracture in an irradiated bone. Physiotherapy during and after radiation genuinely preserves function — start it early rather than once stiffness has set in.
Pre-operative radiation carries a higher rate of wound-healing problems; post-operative radiation uses a larger field and tends to cause more long-term stiffness. Neither is universally better.
Chemotherapy: doxorubicin affects the heart with a tracked lifetime dose; ifosfamide affects the kidneys and bladder and can cause confusion.
How it is assessed: graded at each visit on a standard scale, with limb function, wound healing and cardiac monitoring as relevant.
Follow-up, remission and survivorship
Remission means no detectable sarcoma. Follow-up combines examination and MRI of the primary site with chest imaging, because sarcomas spread to the lungs. Surveillance is most intensive in the first two to three years and continues for ten or more, since late recurrence happens.
Survivorship centres on limb function and rehabilitation — physiotherapy, lymphoedema management, pain, and returning to work and activity. Cardiac monitoring after anthracyclines, and awareness of second cancers in a previously irradiated field, both continue long-term.
If your sarcoma occurred young or there is a family cancer pattern, ask about genetic counselling — Li-Fraumeni and NF1 have real implications for relatives.
Questions people actually ask
I have a lump. When should I worry?
Most lumps are benign. Get one imaged and referred if it is bigger than about 5 cm, sits deep below the muscle layer, is growing, or has become painful. Any one of those is enough.
My GP wants to just remove it. Is that fine?
Not for a deep or large lump. Removing a suspicious lump without planning contaminates the surrounding tissue and usually forces a much bigger operation afterwards. Ask for imaging and a sarcoma referral first — this is the single most consequential thing on this page.
Will I lose my limb?
Almost certainly not. Combining radiation with more conservative surgery achieves the same local control as radical surgery, and limb-sparing treatment is standard for the large majority of extremity sarcomas.
Radiation before or after surgery — which is better?
Both are standard and the trade-off is real. Before surgery uses a smaller field and lower dose but has more wound-healing problems; after surgery uses a larger field and tends to cause more long-term stiffness. It is worth asking your team why they are recommending one for you.
Why is my diagnosis being reviewed again?
Because with more than 70 subtypes, expert sarcoma pathology review changes the diagnosis more often than people expect — and the subtype determines treatment. A second opinion on the pathology is good practice, not a sign something went wrong.
Related pages
See also Keep Bone Cancer Away® for primary bone sarcomas, and Keep Childhood Cancer Away® for sarcomas in children.
Informational only, not medical advice — confirm with your care team.
Go deeper on sarcoma
Read the full plain-language guide, or ask our team about radiation and limb preservation.